Merck KGaA: SpringWorks discussions confirmed
(CercleFinance.com) - On Tuesday Merck KGaA confirmed that it was in advanced discussions with a view to a possible takeover of US biopharmaceutical company SpringWorks Therapeutics, while specifying that no binding agreement had yet been reached.
In a brief statement, the German life sciences specialist - which said it was reacting to press reports - added that there was no certainty that a transaction would take place, and that several critical criteria still needed to be met.
Based in Stamford (Connecticut), SpringWorks specialized in precision oncology with the launch of Ogsiveo (nirogacestat), a treatment for adult patients with progressive desmoid tumors.
Its shares leapt 34% last night in anticipation of a possible takeover by Merck, giving it a market cap of over $4bn.
However, in Frankfurt, Merck shares were down around 0.6% on Tuesday morning following these announcements.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
In a brief statement, the German life sciences specialist - which said it was reacting to press reports - added that there was no certainty that a transaction would take place, and that several critical criteria still needed to be met.
Based in Stamford (Connecticut), SpringWorks specialized in precision oncology with the launch of Ogsiveo (nirogacestat), a treatment for adult patients with progressive desmoid tumors.
Its shares leapt 34% last night in anticipation of a possible takeover by Merck, giving it a market cap of over $4bn.
However, in Frankfurt, Merck shares were down around 0.6% on Tuesday morning following these announcements.
Copyright (c) 2025 CercleFinance.com. All rights reserved.